Abstract
To examine the physiological role of melatonin in sleep, nocturnal melatonin secretion was suppressed using 100 mg oral atenolol in two studies. In Study 1, nocturnal sleep was recorded in 8 young men over 4 nights. Subjects received atenolol on one of the last 2 nights and showed significantly increased total wake time (TWT) and wakefulness after sleep onset (WASO), as well as decreased REM sleep and slow-wave sleep (SWS). When melatonin (total 5 mg) was given after atenolol on the other night, the changes in TWT, WASO, REM, and SWS were reversed. In Study 2, sleep onset latencies (SOL) and core temperature (Tc) of 10 young men were measured for 3 nonconsecutive nights. In a cross-over design, atenolol given on one night significantly suppressed urinary 6-sulphatoxymelatonin (6s-aMT) production and increased hourly measures of Tc and SOL relative to baseline night values. Oral melatonin (3 mg), administered after atenolol, reversed the changes in Tc and SOL. These results suggest that endogenous melatonin may assist in the maintenance of normal sleep architecture (Study 1) and also increase nocturnal sleep propensity by hypothermic effects (Study 2).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 795-802 |
| Number of pages | 8 |
| Journal | Physiology and Behavior |
| Volume | 61 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1997 |
Funding
This work was supported by grants from the National Health and Medical Research Council, Worksafe Australia, and the Australian Government Employees' Medical Research Fund. Thanks to Helen Hayes for help in collecting data in Study 1 and Dr. David Kennaway and Shawn Rowe for 6s-aMT assays in Study 2.
Keywords
- Atenolol
- Core temperature
- Melatonin
- Sleep
- Sleep onset latency
ASJC Scopus subject areas
- Experimental and Cognitive Psychology
- Behavioral Neuroscience